Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in ...
The DecisionDx-Melanoma 31-GEP test recently released top data from the largest prospective GEP study. The study was ...
Dr. Bunick introduces the panel's second case: a 72-year-old retired school administrator with plaque psoriasis diagnosed at ...
Age alone should not dictate biologic hesitancy. The panel challenges the assumption that systemic therapies are inherently riskier in older adults, pointing to safety data and the realities of ...
Two claims analyses of hidradenitis suppurativa showed similar symptom prevalence in males and females and lower dermatologist access among rural patients than urban patients.
Validated screening tools can help, but Friedman said several straightforward questions can also be incorporated into routine visits. He asks patients about prolonged stiffness at rest that improves ...
Sequencing Cryotherapy, Topicals, and PDT in Actinic Keratosis. Bhatia said comprehensive management of actinic keratosis has ...
Hsiao noted the options are adalimumab, a tumor necrosis factor α inhibitor; secukinumab, an IL-17A inhibitor; and ...
In a retrospective study of 393 patients, 51.9% had at least 1 abnormal LFT during follow-up, but only 1.1% had elevations ...
Trotter said dermatologists should pay attention to locally advanced and metastatic cutaneous squamous cell carcinoma (cSCC).
The second day of Fall Clinical 2026 brought new psoriasis data on ixekizumab plus tirzepatide and 2-year icotrokinra results ...
For a patient with atopic dermatitis who is ready for systemic therapy, the first priority is getting them on one, Raj Chovatiya, MD, PhD, MSCI, told Dermatology Times in an interview at. “There ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results